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ABSTRACT 
EVIDENCE-BASED STUDY OF MEDICATION COMPLIANCE PROJECT IN 
HIV PREVENTION USING PRE-EXPOSURE PROPHYLAXIS (PREP) 
ANTIVIRALS FOR HIV-NEGATIVE MALES 
In 2012, emtricitabine/tenofovir was the only Food and Drug Administration-approved 
medication for pre-exposure prophylaxis (PrEP) used in human immunodeficiency virus (HIV) 
prevention. To date, there is little research on open-label and mixed-payer characteristics 
supporting medication compliance of men who have sex with men (MSM). The purpose of this 
research was to describe individual demographic variables associated with PrEP medication 
adherence and to examine the effect of a follow-up phone call from a nurse once a month for 3 
months. A total of 30 MSM were recruited and data were collected using a demographic 
questionnaire, medication adherence tool and follow-up phone calls. Data were analyzed using a 
statistical package. Spearman’s rho correlations demonstrated high medication adherence in 
single men (rs (28) = −.375, p < .05) with no mental health issues (rs (28) = .426, p < .05) and a 
higher educational level (rs (28) = −.431, p < .05). A between group Chi-square demonstrated 
men with high medication adherence and medium medication adherence did not statistically 
differ over 3 months (χ2 (2, N = 28) = .668, p = .71). Individuals who exhibited higher PrEP use 
in an open-label and mixed-payer structure appeared to be young, single, well educated, and 
employed Caucasian gay males with multiple partners. More information will be needed from 
ethnically diverse populations, especially non-Caucasians. Finally, clinical nurses, by supplying 
accountability by phone calls, could improve PrEP compliance by providing planned monthly 
reminders. 
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CHAPTER 1: INTRODUCTION 
Since the 1980s, the human immunodeficiency virus (HIV) infection, which causes 
acquired immunodeficiency syndrome (AIDS), has been a global epidemic. The Centers for 
Disease Control (CDC) estimates the number of people living with HIV in the United States at 
approximately 1.2 million, and roughly 44,000 individuals are newly diagnosed with HIV each 
year (CDC, 2015). HIV is a costly disease; the on-going cost to manage HIV is estimated at 
$379,668 per person annually (in 2010 USD; CDC, 2015). Men who have sex with men (MSM) 
continue to be a more vulnerable to contracting HIV than men who have heterosexual sex. MSM 
may have recurrent exposure to HIV that is compounded by high-risk sexual behavior (e.g., 
multiple partners, unprotected sex, or drug abuse). Lelutiu-Weinberger et al. (2013) estimated 
that gay men represent 54% of HIV infections in the United States. Even though eradication of 
HIV remains elusive, highly active antiretroviral therapy has been promising for suppressing the 
virus and reducing HIV transmission. Treatment as prevention has been highly adapted to current 
HIV medical care. In addition, scientific clinical research has proven the effectiveness of using 
antiretroviral therapy in conjunction with condom us as prophylaxis for lowering the risk of 
contracting HIV infection (CDC, 2018). 
Since 2012, when the Food and Drug Administration (FDA) approved pre-exposure 
prophylaxis (PrEP) for HIV prevention, the demand for PrEP utilization has increased; however, 
accessing PrEP has many challenges. Recent PrEP literature reviews, as applied to PrEP research 
projects, demonstrate that emtricitabine/tenofovir is an effective oral medication for hindering 
HIV transmission when used in a continuous daily regimen. However, in a real-world clinical 
practice, there are challenges for PrEP compliance in the MSM population. Patients encounter 
obstacles to complying with the daily regimen, fail to follow through with their quarterly medical 
visits, experience side effects to the medication, or find themselves with a financial burden if 
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their insurance does not cover the medication. Thus, evidence-based research was needed to 
address those issues. Throughout this research review, the correlation of PrEP compliance factors 
in an open-label and mixed-payer structure for the MSM HIV-negative population needed to be 
understood so the gap in research could be filled. This PrEP study seeks to understand the PrEP 
compliance proclivities of the MSM population. Moreover, this PrEP compliance study will 
analyze the evidence-based research of monthly follow-up phone calls to showcase that nursing 
intervention could improve medication compliance in HIV prevention. 
Theoretical Framework 
Jean Watson’s human caring theory, which focuses on patient- and family-centered 
collaborated care, is applicable in all care settings. The medication adherence issue is a major 
obstacle crossing the spectrum of disease management and prevention. Behavior change theory, 
which explains patients’ behavior in regard to their attitude toward medication adherence and 
their health outcome, is predominately used for medication adherence. This PrEP compliance 
project takes the nursing perspective for factors that support patients’ medication adherence 
behavior. Thus, Watson’s human caring theory has been implemented and applied as a 
theoretical framework for this PrEP compliance evidence-based study. 
Stanford Health Care (SHC) defines the nurse’s profession practice model as affecting 
the patient’s health outcome by addressing the patient’s mind, body, and soul (SHC, 2015). In 
addition, patient centered care affects families, communities, and populations as a whole. In 
human caring theory, Watson (1988) explains that the major conceptual elements are carative 
factors, transpersonal caring relationships, and caring moments/caring occasions. The 10 carative 
factors are the groundwork for developing the nurse-patient relationship for fostering the 
problem-solving caring process; this translates into HIV prevention by providing holistic care for 
individual patients, whether healthy or sick. Furthermore, nursing care for HIV prevention is 
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amplified to protect the partner, family, and then the community for achieving a zero HIV 
infection rate. 
The assumption of the human caring theory is based on a nurse who commits to his or her 
practice and is consciously aware of the need for human dignity while providing healing in the 
care environment. This mindset allows patients to heal and reach their optimum healthcare 
outcomes. The PrEP compliance project is a patient-centered care approach to HIV prevention. 
The nurse takes the initiative and looks for ways to improve adherence to a daily medication 
regimen. Watson’s human caring theory explains the patient-centered approach, combining 
spirit, body, and soul, for optimizing the patient’s healthcare outcome as a whole entity; this puts 
the HIV prevention project in focus from individual health to community health. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
Several studies have examined the use of pre-exposure prophylaxis (PrEP) using 
antivirals emtricitabine/tenofovir in HIV-negative subjects. In what is known as the iPrEx study, 
Grant et al. (2010) used a randomized double-blind placebo-controlled study of 
emtricitabine/tenofovir by sampling 2,499 HIV-negative MSM and transgender women. One 
group received oral antiretroviral medications daily, while the other received a placebo. Using 
regression statistics to show the effectiveness of PrEP, Grant et al. found a 44% reduction rate of 
HIV infection in the target group over the control group. The reduction of the HIV infection risk 
was between 92% and 95% while blood medication concentration levels reached therapeutic 
range. This research was the first study to prove PrEP utilization for HIV prevention. The 
strength of the study was its large sample size and the high quality of data gathered, especially in 
medication monitoring. The quality of the research lay in its protocol. However, the limitation of 
the study was the investigators’ failure to distinguish high-risk sexual behavior of those with 
multiple sex partners or those with single episodes of condomless sex with the same partner. 
To challenge daily consumption of emtricitabine/tenofovir, Kibengo et al. (2013) 
conducted a double-blind randomized study, known as the intermittent PrEP study, to 
demonstrate the effectiveness of the drug. Kibengo et al. sampled 72 HIV serodiscordant (one 
partner HIV positive, the other HIV-negative) couples in two groups. One group using an oral 
regimen within 2 hours after sex, not to exceed one dose per day while the other group followed 
a daily oral regimen. Both regimens were equally effective, yet the adherence rates in the 
intermittent group were 91% compared to 98% in the daily regimen group. Kibengo et al. 
suggest that PrEP could be considered if accessing medication is an issue. One of the strengths of 
this study was that the data was collected in real time using a smartphone daily or within 24 
hours of a sexual encounter. A limitation included false data regarding medication consumption 
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if someone opened the electronic calculated pillbox but did not take the medication. Further 
limitations included a small sample size (N = 72) that was not large enough to generalize. In a 
side note, the intermittent use of emtricitabine/tenofovir has not been FDA approved in the 
United States. 
In the partners PrEP study, Murnane et al. (2015) used randomized double-blind placebo-
controlled emtricitabine/tenofovir versus tenofovir only. Murnane et al. studied 4,747 HIV 
serodiscordant heterosexual couples and used stratification and inverse probability of censoring 
weights and per-protocol analysis to determine the efficacy and safety of emtricitabine/tenofovir 
and tenofovir. They found that daily emtricitabine/tenofovir or tenofovir intake each yielded an 
80% reduction of HIV compared to the placebo group and suggested that consuming a daily 
regimen consistently yields the highest safety and effectiveness level of HIV prevention. One of 
the partners PrEP study strengths was the large sample size with a quality randomized and 
double-blind setup; however, the study’s limitation was the pill count method, which may be 
inaccurate (e.g., pill dumping could yield false results). Overall, Murnane et al.’s (2015) research 
findings supported Grant et al.’s (2010) iPrEx study results for daily consumption of 
emtricitabine/tenofovir. Despite the large sample size, use of tenofovir alone has not been FDA 
approved in the United States. 
Gamarel and Golub (2015) tried to determine the intention of 164 HIV-negative MSM to 
adopt PrEP. Researchers used regression models and ANOVA to compare the tendency to adopt 
a PrEP regimen by age, income, and education. They found that motivation for condomless sex 
is accompanied by adopting PrEP by MSMs despite their age, income, and education. One 
strength of Gamarel and Golub’s research was the receipt of localized data from a metropolitan 
area, which allowed for a significant descriptive statistical analysis pertinent to the study of 
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metropolitan phenomena. One of this study’s limitations was that several MSM participants 
answered the questions based on hypothetical situations rather than an actual situation. 
Mathur et al. (2016) conducted interviews and group discussions to elucidate cultural 
barriers affecting HIV prevention. Researchers sampled 24 discussion groups and conducted 24 
comprehensive interviews to identify the nature of HIV perception and sexual risk assessment of 
youth and adults in Uganda. The researchers used “systematic analysis of narrative data” to 
generate the major themes by “across-case analysis” (p. 1). Mathur et al. found that generational 
conceptual differences affect HIV prevention in Uganda. The major cultural themes are fear, 
skepticism, and misconceptions about the HIV prevention message. The researchers suggest 
focusing on “disseminating HIV prevention knowledge that is tailored to generational 
differences” (p. 9). One of the strengths of this research was the qualitative design with in-depth 
follow-up interviews for identifying major themes. One of the limitations was that the 
interviewers may have had biases concerning the interviewees’ answers, and the responses could 
have been misinterpreted. 
Marcus et al. (2016), in a study known as the Kaiser PrEP study, conducted a cohort 
study of 972 MSM members at Kaiser Permanente Northern California using electronic medical 
record chart review in an open-label use of emtricitabine/tenofovir. Marcus et al. tried to 
determine the level of medication adherence/discontinuation, renal safety, and incidence of 
sexually transmitted infection and HIV infection. Findings revealed no incidences of new HIV 
infection during the 2.5 years of investigation. Marcus et al. concluded that being an African 
American, smoking, and having a high copay Kaiser insurance plan was associated with a low 
adherence to PrEP compliance. Marcus et al. suggested quarterly screenings to provide a 
baseline for healthcare maintenance and to improve PrEP adherence. One of the strengths in the 
Kaiser PrEP study was that it was open label in a large cohort within different locations in 
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Northern California. However, one weakness in the Kaiser PrEP study was that the study cohort 
did not represent the mix of payers in a majority of healthcare settings because the study 
participants were all covered by Kaiser insurance. 
A review of the literature was undertaken to examine PrEP utilization in HIV prevention. 
Multiple studies (Grant et al., 2010; Kibengo et al., 2013; Murnane et al., 2015) have shown that 
oral antiretroviral use reduces HIV transmission to sexual partners. Other studies (Gamarel & 
Golub, 2015; Mathur et al., 2016; Marcus et al., 2016) have discussed individual adoption (or 
nonadoption) of HIV transmission prevention measures. This review demonstrates the need to 
fill the research gaps to determine the factors associated with PrEP compliance in the individual. 
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CHAPTER 3: METHODS 
Design 
This evidence-based project was a descriptive, correlational, longitudinal study using a 
convenience sample of HIV-negative males. The purpose of this research was to describe 
individual demographic variables associated with PrEP medication adherence and to examine the 
effect of a follow-up phone call from a nurse once a month for 3 months. Participants were HIV-
negative men who had sex with men (MSM) in a mixed-payer, open-label, and outpatient care 
structure. The hypothesis was to find a positive relationship between less medical issues, less 
mental health issues, higher socioeconomic status and high level of MSM medication adherence. 
In addition, another aim was to determine the effects of follow-up phone call on medication 
adherence if provided by a clinical nurse once a month for 3 months. 
Setting 
The PrEP evidence-based study was conducted at a large outpatient clinic in Northern 
California. The clinic provided comprehensive HIV and STD care to the lesbian, gay, bisexual, 
transgender, questioning (LGBTQ) populations from Santa Clara, Alameda and San Francisco 
Counties. The clinic emphasized HIV prevention and was a member of Santa Clara’s “Getting to 
Zero” campaign, whose mission has been to increase HIV/AIDS awareness and to reach a zero 
HIV transmission rate in the local LGBTQ population. The clinic was staffed by three medical 
doctors, one physician assistant, two psychiatrists, one clinical nurse, and one medical assistant. 
All medical staff members were trained and educated regarding PrEP education. 
Sample Population 
The clinic had approximately 100 homosexual, heterosexual, or bisexual patients enrolled 
quarterly for PrEP. The ethnicity of patients was 47.1% Hispanic, 29.1% Caucasian, 14.5% 
African American, and 8.4% Asian. Males represent 82%, females represent 15.8%, and 
9 
transgender people represent 2% (E. Brooks, personal communication, November 1, 2016). The 
project focused on recruiting the gay HIV-negative MSM population who took daily HIV 
prevention oral antivirals. 
Ethical Considerations 
On August 1, 2017, the local hospital and clinic system Institutional Review Board (IRB) 
approved the project (see Appendix A). The study timeframe was from September 2017 to 
February 2018. Approval was also obtained from a university IRB. Consent was obtained by the 
clinical nurse (see Appendix B). Potential risks were addressed: participants could experience 
psychological stress while completing the survey questionnaire, to include emotional discomfort, 
embarrassment, and anxiety. To minimize psychological stress, the clinical nurse emphasized 
that the study was voluntary. Participants were free to decline to answer any questions that made 
them uncomfortable. Participants were informed that they could withdraw from the study at any 
time without penalty or prejudice and that they would not be asked why they were withdrawing. 
Other potential risks included that participants could worry that the survey would 
negatively affect their insurance and medical benefits. The clinical nurse reassured participants 
that their anonymity would not be violated and the subject and data would be held in confidence 
and would not be used against the participants’ rights. Participants were granted free access to 
the onsite library where medical and psychological resources were available for information 
prior to joining the study. 
This study strictly complied with HIPAA and information security requirements. The 
participants’ names and medical record numbers were not linked to the survey, instead subjects 
were randomly identified a number. The completed survey forms, the consent forms, and the 
medication compliance questionnaires were secured in a locked drawer in the unit office. The 
10 
access key could be obtained only from the clinical nurse or clinic manager. There were no 
personal computers, USB drives, external hard drives, tablets, or smartphones used in this study. 
Procedure 
The frontline providers identified the inclusion candidates after meeting the subjects in 
the clinic setting; the physician or physician assistant then notified the clinical nurse. The 
population of interest were male, men who have sex with men (MSM) who requested 
emtricitabine/tenofovir for HIV prevention. The inclusion criteria for participants included naïve 
or new patients who were seeking a PrEP regimen or current existing patients on a PrEP regimen 
without previous failure. The exclusion criteria were patients who had a failure history on PrEP 
or who had been consistently in and out of the PrEP program. 
The clinical nurse initiated an individual 10-minute face-to-face study consultation with 
each MSM candidate and obtained written legal consent during that visit. The clinical nurse also 
informed participants of the research purpose, benefits, risks, and compensation. Candidates who 
agreed to participate in the study received a $5 gift card and a $1 scratch lottery ticket as 
compensation. The clinical nurse then explained and had the candidate take the survey. 
The clinical nurse instructed participants about a medication-monitoring phone consult 
that would continue for 10-minutes via phone once a month for a 3-month period. The follow-up 
phone call would include questions about emtricitabine/tenofovir and 4-questions from the 
Morisky’s Medication Adherence Scale. Participants would be discharged from the study after 
data collection was completed. 
Instrument 
The clinical nurse distributed a survey (see Appendix C). The survey consisted of nine 
demographic questions and the 4-item Morisky’s Medication Adherence Scale (MMAS-4). The 
MMAS-4 instrument developed by Morisky et al. (1986) has been tested for predictive validity 
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of self-reporting measures (alpha reliability = 0.61). The MMAS-4 has been taken under a 
control group environment showing high adherence reliability (p <0.01). 
The instrument was initially used with hypertensive patients for medical providers to 
follow-up on patients’ behavior changes when self-scoring via MMAS-4. In addition, the 
validated MMAS-4 instrument has been cited by more than 300 articles in various settings, 
including diabetes, COPD, and hypertension. MMAS-4 was the first to be used in a HIV PrEP 
compliance study. The tool consists of the four questions listed below: 
1. Do you ever forget to take your medicine? 
2. Are you careless at times about taking your medicine? 
3. Sometimes if you feel worse when you take the medicine, do you stop taking it? 
4. When you feel better, do you sometimes stop taking your medicine? 
The answer to each MMAS-4 question is either yes or no. Patients who answer yes 
receive one point. A total score of 3–4 indicates low adherence, 2–3 indicates medium 
adherence, and 0–1 indicates high adherence. The potential limitation of the instrument was that 
“the tool could not distinguish the trend of medium adherence” (Morisky et al., 1986, p. 72). 
Thus, the MMAS-4 results can be skewed if the subject is either high adherence or low 
adherence. 
Data Analysis Plan 
Data analysis were conducted with a statistical program for social sciences. Spearman’s 
rho was used to test the correlation between categorical variables (i.e., age, marital status, sexual 
relationships, medical status, mental health status, ethnicity, education level, employment status, 
and income) and the MMAS-4 score. Correlations helped predict which variables were 
associated with compliance in the MSM population in an ambulatory setting. Furthermore, chi-
square tests could demonstrate medication adherence within groups. 
12 
CHAPTER 4: RESULTS 
A total of 30 HIV-negative MSMs were recruited for the PrEP compliance study. One 
participant dropped out of the study, and another was instructed to stop the regimen because of 
an increase of liver and kidney enzymes. In total, N = 28 HIV-negative MSMs participated in the 
study. 
The demographics of age, marital status, relationship status, mental health status, 
education level, employment status, and annual income were analyzed (see Table 1). Study 
participants were males under 40 years of age (n = 20, 71.4%). Most participants reported that 
they were single (n = 19, 67.9%) and had more than two sexual partners or were in open 
relationships (n = 19, 67.9%). Most participants had few medical issues or no mental health 
issues (n = 23, 82.1%). Participants self-reported their ethnic backgrounds as Caucasian (n = 14, 
50%), Hispanic (n = 9, 32.1%), and Asian (n = 5, 17.9%). The majority of study participants 
were employed (n = 25, 89.3%) with college or postgraduate degrees (n = 24, 85.7%) and an 
annual household income of over $75,000 per year (n = 15, 53.6%). 
Table 1 
Sample Demographics 
Age in Category Frequency n = Percent % 
18–39 years old 20 71.4 
40–49 years old 6 21.4 
50–59 years old 2 7.1 
Marital Status  
Single 19 67.9 
Married 4 14.3 
Partnered, Not Married 3 10.7 
Divorced or Separated 2 7.1 
13 
Relationships  
1 Sex Partner 4 14.3 
>2 Sex Partners 15 53.6 
Open Relationship 4 14.3 
Other 5 17.9 
Medical Status  
No Medical Issue 13 46.4 
1 Acute Medical Issue 6 21.4 
1 Chronic Medical Issue 8 28.6 
>2 Acute Medical Issues 1 3.6 
Mental Health Status  
No Mental Health Issue 23 82.1 
1 Medication for Mental Issue 4 14.3 
>2 Medications for Mental Issue 1 3.6 
Ethnic Background  
Asian 5 17.9 
Hispanic 9 32.1 
White 14 50.0 
Education Level  
Some College 4 14.3 
College or Post-Grad 24 85.7 
Employment Status  
Employed 25 89.3 
Unemployed 2 7.1 
Student 1 3.6 
Annual Household Income  
<$20,000 1 3.6 
$40,001~$75,000 12 42.9 
>$75,001 15 53.6 
Time 1 Month MMAS-4  
High Adherence 13 46.4 
Medium Adherence 15 53.6 
Time 2 Months MMAS-4  
High Adherence 16 57.1 
Medium Adherence 12 42.9 
Time 3 Months MMAS-4  
High Adherence 15 53.6 
Medium Adherence 13 46.4 
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Spearman’s rho correlations were conducted to determine whether any relationships 
existed between demographic variables and medication adherence at 1 month, 2 months and 3 
months (see Table 2). A two-tailed test of significance indicated a significant negative 
relationship between marital status and medication adherence at 1 month, rs (28) = −.375, p < 
.05. A single male had higher medication adherence. A two-tailed test of significance indicated a 
significant positive relationship between mental health status and medication compliance at 1 
month, rs (28) = .426, p < .05. Participants with no mental health issues had higher medication 
compliance. Finally, a two-tailed test of significance indicated a significant negative relationship 
between the participant’s education level and medication compliance at 2 months, rs (28) = 
−.431, p < .05. Participants with postgraduate degrees had higher medication compliance. 
Spearman’s rho correlations were also conducted to determine whether any relationships 
existed between medication adherence at 1 month, 2 months, and 3 months. A two-tailed test of 
significance indicated a highly significant positive relationship between medication adherence at 
1 month and 2 months, rs (28) = .521, p < .01; at 1 month and 3 months, rs (28) = .490, p < .01; 
and at 2 months and 3 months, rs (28) = .806, p < .01. Participants had a consistent level of 
medication adherence over 3 months. Participants who had moderate medication adherence 
tended to predict moderate medication adherence over 3 months. Participants who had high 
medication adherence tended to predict high medication compliance over 3 months. 
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Table 2 
Spearman’s rho Correlations 
 
Age 
Marital 
Status 
Relations 
Medical 
Status 
Mental 
Health 
Ethnic 
Ed 
Level 
Employ 
Status 
Annual 
Income 
Time 1 
mos. 
MMAS 
Time 2 
mos. 
MMAS 
Time 3 
mos. 
MMAS 
Age CC 1.000 .019 .113 -.464* .290 .480** -.065 .035 .124 .053 .145 -.055 
Sig. . .924 .568 .013 .135 .010 .744 .860 .531 .787 .462 .780 
Marital 
Status 
CC .019 1.000 -.125 -.179 -.159 .071 .058 .208 .045 -.375* -.304 -.338 
Sig. .924 . .527 .361 .420 .719 .769 .288 .819 .049 .116 .079 
Relations CC .113 -.125 1.000 .128 .298 .033 .372 -.117 .063 -.116 -.267 -.285 
Sig. .568 .527 . .516 .124 .869 .051 .553 .748 .558 .170 .141 
Medical 
Status 
CC -.464* -.179 .128 1.000 .126 -.128 -.123 .106 .316 .062 .048 .068 
Sig. .013 .361 .516 . .522 .516 .534 .592 .102 .755 .810 .730 
Mental 
Health 
CC .290 -.159 .298 .126 1.000 .440* .063 .207 -.060 .426* .253 .252 
Sig.  .135 .420 .124 .522 . .019 .751 .291 .762 .024 .194 .196 
Ethnic CC .480** .071 .033 -.128 .440* 1.000 -.017 .049 .041 -.013 .168 -.018 
Sig. .010 .719 .869 .516 .019 . .933 .803 .837 .947 .393 .926 
Ed 
Level 
CC -.065 .058 .372 -.123 .063 -.017 1.000 -.030 .119 -.116 -.431* -.367 
Sig. .744 .769 .051 .534 .751 .933 . .879 .548 .555 .022 .055 
Employ 
Status 
CC .035 .208 -.117 .106 .207 .049 -.030 1.000 .030 -.017 .021 .014 
Sig. .860 .288 .553 .592 .291 .803 .879 . .881 .932 .917 .945 
Annual 
Income 
CC .124 .045 .063 .316 -.060 .041 .119 .030 1.000 -.014 -.234 -.306 
Sig. .531 .819 .748 .102 .762 .837 .548 .881 . .944 .232 .113 
Time 1 
mos. 
MMAS 
CC .053 -.375* -.116 .062 .426* -.013 -.116 -.017 -.014 1.000 .521** .490** 
Sig. .787 .049 .558 .755 .024 .947 .555 .932 .944 . .005 .008 
Time 2 
mos. 
MMAS 
CC .145 -.304 -.267 .048 .253 .168 -.431* .021 -.234 .521** 1.000 .806** 
Sig. .462 .116 .170 .810 .194 .393 .022 .917 .232 .005 . .000 
Time 3 
mos. 
MMAS 
CC -.055 -.338 -.285 .068 .252 -.018 -.367 .014 -.306 .490** .806** 1.000 
Sig. .780 .079 .141 .730 .196 .926 .055 .945 .113 .008 .000 . 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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In the first month of nursing follow-up phone calls, the results showed that single 
MSM participants correlated with high medication compliance, as did participants with no 
mental health issues. For the second and third month follow-ups, the data showed that a higher 
education level correlated with high medication compliance. The study results demonstrated that 
in an open-label and mixed-payer structure of compliance, being single, having a high education 
level, and not having a mental health diagnosis correlated with a high level of PrEP compliance. 
Even though the nurse’s follow-up phone calls did not prove to be significant in increasing 
medication adherence, the nursing follow-up intervention demonstrated that the phone calls 
served as accountability for maintaining patients’ adherence levels through the 3-month period. 
A chi-square test of independence was performed to determine group adherence over 
time. The chi-square test aimed to determine whether the medication adherence level differed 
between 1 month, 2 months, and 3 months. The result of chi-square test showed that the 
percentage of patients with high adherence and the percentage of patients with medium 
adherence did not statistically differ between the three-time points, χ2 (2, N = 28) = .668, p = .71 
(see Table 3). The high adherence group, remained at high adherence with medication over 3 
months. The medium adherence group, remained at medium adherence with medication over 3 
months. There were no subjects with low adherence. 
Table 3 
Chi-square Tests 
Chi-Square Tests 
 
Value df 
Asymptotic 
Significance (2-
sided) 
Pearson Chi-Square .668a 2 .716 
Likelihood Ratio .669 2 .716 
Linear-by-Linear Association .283 1 .595 
N of Valid Cases 84   
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There was no statistical significance to prove that a nurse’s follow-up phone calls 
improved patient adherence from medium to high adherence. The adherence levels did not 
change over 3 months. As a result, the nurse’s follow-up phone calls may have served to sustain 
medication compliance from changing throughout the 3-month period. 
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CHAPTER 5: DISCUSSION 
Results described individual demographic variables associated with MSM and 
medication adherence. The first hypothesis was to find a positive relationship between MSM and 
less medical issues, less mental health issues, and higher socioeconomic status with a high level 
of medication adherence. Results demonstrated that there was a relationship between no mental 
health issues and a high level of medication adherence. However, there was not a relationship 
between no medical issues or higher socioeconomic status. Instead, findings suggested that a 
single male with no mental health issue and higher education had a strong relationship with high 
medication adherence in an open-label and mixed-payer structure of healthcare. 
Previous studies (Grant et al., 2010; Kibengo et al., 2013; Murnane et al., 2015) have 
shown that HIV transmission was greatly reduced in HIV-negative partners on oral 
antiretrovirals. In comparison to these investigations, no HIV infection was reported by study 
subjects. During the short study timeframe, the effectiveness in HIV prevention associated with 
iPrEx (2010) and Partners PrEP (2015) was also seen in this investigation. Although, these 
previous studies (Grant et al., 2010; Kibengo et al., 2013; Murnane et al., 2015) supported the 
use of PrEP compliance, little information was given on the type of subject who would have 
medication compliance. Again, this research suggested that single males with no mental health 
issues and higher education levels had high medication compliance. 
Other studies (Gamarel & Golub, 2015; Mathur et al., 2016; Marcus et al., 2016) have 
discussed individual adoption (or nonadoption) of HIV transmission prevention measures. 
Gamarel and Golub (2015) noted that regardless of age, income or education the motivation to 
adopt PrEP was related to condomless sex. In Uganda, Mathur et al. (2016) found that 
participants were less likely to adopt PrEP due to fear, skepticism and misconceptions. Marcus et 
al., found that being African American, smoking and having a higher insurance copay was a 
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deterrent to PrEP adoption. The participants in this study sample were primarily Caucasian 
MSM who were younger (18-39 years of age) single, in multiple relationships, without medical 
or mental issues, were employed with college or postgraduate degrees. 
Limitations 
Limitations included a small sample size, the setting, and the short length of the project. 
First, anecdotally, it appeared that participants did not show an interest in study participation and 
receiving follow-up phone calls, perhaps due to social stigma, resistance to being labeled, or 
disinterest toward phone calls about medication adherence. Second, the patient volume and 
traffic was insufficient to recruit a large sample size. A multi-site study involving different 
settings may have yielded a larger sample. The location of the study, in an area of high education 
and affluence did not necessarily represent typical healthcare settings across the United States. 
As a result, the study only represented the local population. Third, the study was of short 
duration and as a result recruitment discontinued in order to not exceed the project timeline. The 
study design of 3 months may not have been long enough to be demonstrating long-term PrEP 
compliance. Conceivably, 6 or 12 months of follow-up phone calls may have been ideal to 
provide stronger statistical evidence in support of PrEP compliance. 
Conclusion 
This descriptive study demonstrated higher PrEP compliance in young, single, educated, 
and employed Caucasian gay males with multiple partners. Study results represented an affluent 
urban metropolitan area in a care setting for an open-label and mixed-payer structure. The 
convenience population did not necessarily represent settings across the United States because of 
the specific location with higher levels of education and income. More information will be 
needed about the variables affecting PrEP compliance in other settings. 
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In addition, more studies need to look at human variables associated with clients that 
are of different race and ethnic backgrounds. Although, African Americans represent 14.5% of 
the clinic population, none were recruited into the convenience sample during the study 
timeframe. Further studies need to be conducted on HIV-negative issues, including sexual 
education, social stigma, gay culture, and sexual behaviors, especially concerning young MSMs 
of color. 
It is important for clinical nurses to understand individual human variables related to 
HIV-negative antiviral medication compliance. Although no statistical significance was seen 
between groups with regards to medication adherence, findings suggest that clinical nurses may 
reinforce medication adherence by providing planned follow-up phone calls. Holistic care via the 
human caring theory seeks to achieve human wellbeing by nursing care support. 
In conclusion, clinical nurses can support clients in achieving the highest level of HIV 
prevention and health outcomes. HIV prevention affects patients’ partners, families, and 
communities. Finally, the goal of HIV prevention is to reach a zero-transmission rate in the 
community, and ultimately end the AIDS epidemic. 
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CONSENT FORM 
For MINIMAL RISK Medical Human Subject Research 
 
FOR QUESTIONS ABOUT THE STUDY, CONTACT: Edward Brooks, MD, Chief 
Medical Director and Ming-Chun Ho, MSN, RN. Address: 211 Quarry Road, Suite 202, Palo 
Alto, CA 94304. Phone number: 650-723-9001. 
 
DESCRIPTION: You are invited to participate in a research study on Pre-exposure 
Prophylaxis (PrEP) Antivirals for HIV Negative Males Medication Compliance study. The 
purpose of the study is to fill the gap in the research reviews and provide further evidence for 
institution to support PrEP adherence. You will be asked two pages of questionnaires about the 
medical, psychosocial, and financial status with basic demographic information. After 
complete the survey form, you will be asked to follow up the monthly self-report medication 
compliance questionnaires, which is 4 questions total, via a phone call from September 1st, 
2017 through February 28th, 2018. These questionnaires should take about 10 minutes to 
complete. 
The results of the study of your samples will be used for research purposes only and you will not 
be told the results of the tests. 
 _____ I consent to my samples being saved for future research 
 _____ I do not consent to my samples being saved for future research 
 
RISKS AND BENEFITS: The risks associated with this study are none, and you are free to 
decline any questions, which make you feel uncomfortable. The benefits which may 
reasonably be expected from this study are none. However, by understanding the correlation 
factors associated with PrEP medication compliance via this study, the future patients will be 
benefit by standardized PrEP protocol to achieve higher medication adherence rate. We cannot 
and do not guarantee or promise that you will receive any benefits from this study. Your 
decision whether or not to participate in this study will not affect your employment/medical 
care. 
 
TIME INVOLVEMENT: Your participation in this experiment will take approximately 10 
minutes. 
 
PAYMENTS: You will receive $5 Starbucks gift care and a $1 scratch-off ticket as payment 
for your participation. There is no cost for you to participate in this study. 
 
PARTICIPANT’S RIGHTS: If you have read this form and have decided to participate in 
this project, please understand your participation is voluntary and you have the right to 
withdraw your consent or discontinue participation at any time without penalty or loss of 
benefits to which you are otherwise entitled. 
The results of this research study may be presented at scientific or professional meetings or 
published in scientific journals. However, your identity will not be disclosed. You have the 
right to refuse to answer particular questions. 
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Authorization to Use Your Health Information for Research Purposes 
 
Because information about you and your health is personal and private, it generally cannot be used in this 
research study without your written authorization. If you sign this form, it will provide that authorization. 
The form is intended to inform you about how your health information will be used or disclosed in the 
study. Your information will only be used in accordance with this authorization form and the informed 
consent form and as required or allowed by law. Please read it carefully before signing it. 
 
What is the purpose of this research study and how will my health information be utilized 
in the study? 
The purpose of the study is to fill the gap in the research reviews and provide further evidence for 
institution to conduct standardized PrEP protocols to support PrEP adherence. Your health information 
will be desensitized by randomly assigned two-digit number, which only Ming-Chun Ho, RN able to 
identify on a Stanford password protected computer via electronic medical record for HIV negative result. 
No health information will be linked to the paper questionnaires. 
 
Do I have to sign this authorization form? 
You do not have to sign this authorization form. But if you do not, you will not be able to participate in 
this research study. Signing the form is not a condition for receiving any medical care outside the study. 
 
If I sign, can I revoke it or withdraw from the research later? 
If you decide to participate, you are free to withdraw your authorization regarding the use and disclosure 
of your health information (and to discontinue any other participation in the study) at any time. After any 
revocation, your health information will no longer be used or disclosed in the study, except to the extent 
that the law allows us to continue using your information (e.g., necessary to maintain integrity of 
research). If you wish to revoke your authorization for the research use or disclosure of your health 
information in this study, you must write to: Ming-Chun Ho, MSN, RN. Address: 211 Quarry Road, Suite 
202, Palo Alto, CA 94304. 
 
What Personal Information Will Be Obtained, Used or Disclosed? 
Your health information related to this study, may be used or disclosed in connection with this research 
study, including, but not limited to, age, marital status, sex relationship, medical and mental status, ethnic, 
employment status, household income, and HIV status. The protocol director: Edward Brooks, MD and 
admin contact: Ming-Chun Ho, MSN, RN will only use electronic medical records (EMRs) to identify 
and confirm your HIV-negative status for eligibility purposes. No specimens will be collected. In a paper 
format, your names and medication record numbers will be desensitized by randomly assigned two-digit 
numbers, which only the Ming-Chun Ho, MSN, RN will able to identify on a Stanford password 
protected and information secured computer via EMRs. No health information will be linked to the paper 
questionnaires. 
 
Who May Use or Disclose the Information? 
The following parties are authorized to use and/or disclose your health information in connection with 
this research study: 
 The Protocol Director: Edward Brooks, MD, Chief Medical Director 
 The Stanford University Administrative Panel on Human Subjects in Medical Research and any 
other unit of Stanford University as necessary 
 Admin Contact: Ming-Chun Ho, MSN, RN 
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Who May Receive or Use the Information? 
The parties listed in the preceding paragraph may disclose your health information to the following 
persons and organizations for their use in connection with this research study: 
 The Office for Human Research Protections in the U.S. Department of Health and Human 
Services 
Your information may be re-disclosed by the recipients described above, if they are not required by law to 
protect the privacy of the information. 
When will my authorization expire? 
Your authorization for the use and/or disclosure of your health information will end on February 28, 2018 
or when the research project ends, whichever is earlier. 
Will access to my medical record be limited during the study? 
To maintain the integrity of this research study, you may not have access to any health information 
developed as part of this study until it is completed. At that point, you would have access to such health 
information if it was used to make a medical or billing decision about you (e.g., if included in your 
official medical record). 
 
________________________________               ______________ 
Signature of Adult Participant                                           Date 
 
 
________________________________             
Print Name of Adult Participant 
 
 
WITHDRAWAL FROM STUDY 
The Protocol Director may also withdraw you from the study without your consent for one or more of 
the following reasons: 
o Failure to follow the instructions of the Protocol Director and study staff. 
o The Protocol Director decides that continuing your participation could be 
harmful to you. 
o You need treatment not allowed in the study. 
o The study is cancelled. 
o Other administrative reasons. 
o Unanticipated circumstances. 
 
CONTACT INFORMATION:  
Questions, Concerns, or Complaints: If you have any questions, concerns or complaints about this 
research study, its procedures, risks and benefits, or alternative courses of treatment, you should ask the 
Protocol Director, Edward Brooks, MD, Chief Medical Director. You may contact him now or later at 
650-723-9001. 
 
If you have any questions, concerns or complaints about this research study, its procedures, risks and 
benefits, or alternative courses of treatment, you should ask the Protocol Director, Edward Brooks, MD, 
Chief Medical Director at 650-723-9001. You should also contact him at any time. 
The extra copy of this signed and dated consent form is for you to keep. 
________________________________    ________________ 
Signature of Adult Participant      Date 
 
_____________________________________ 
Print Name of Adult Participant 
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Mark an X in the box that best describes YOU: 
Your Age? 
 18-39               1 
 40-49               2 
 50-59               3 
 >60               4 
Your marital status? 
 Single               1 
 Married               2 
 Partnered, Not Married               3 
 Divorced or Separated               4 
 Widowed               5 
Your sex relationship status? 
 One sex partner               1 
 >2 sex partners                2 
 Open relationship               3 
 Other:                                         4 
Your medical status? 
 One acute medical issue                1 
 One chronic medical issue               2 
 >2 acute medical issue               3 
 >2 chronic medical issue               4 
Your mental health status? 
 No mental health issue               1 
 One medication for mental health    2 
 >2 medications for mental health   3 
Your ethnic background? 
 Asian               1 
 Black               2 
 Filipino               3 
 Hispanic               4 
 Native American               5 
 Pacific Islander               6 
 White               7 
 Other               8 
Check your highest level of education completed: 
 Elementary               1 
 Some High School               2 
 High School Diploma               3 
 Some College               4 
 College Degree               5 
 Post-Graduate Degree              6 
APPENDIX C: SURVEY INSTRUMENT 
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Your employment status? 
 Employed               1 
 Unemployed               2 
 Homemaker               3 
 Retired               4 
 Student               5 
Your gross annual (yearly) household income? 
 
 No income               1 
 < less than $20,000               2 
 $20,000 - $40,000               3 
 $40,001 - $75,000               4 
 $75,001 - $100,000               5 
 >$100,001                6 
 
Thank you for your participation. 
You will receive a monthly phone call for follow up your compliance. 
 
Monthly self-report phone interview questions that best describes YOU: 
 
Do you ever forget to take your medication?                                                           Yes     No 
 
Are you careless at times about taking your medication?                                        Yes     No 
 
When you feel better do you sometimes stop taking your medicine?                      Yes     No 
 
Sometimes if you feel worse when you take the medicine, do you stop taking it?   Yes     No
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